Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
129 hedge funds and large institutions have $1.35B invested in Aimmune Therapeutics in 2017 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 33 increasing their positions, 42 reducing their positions, and 11 closing their positions.
273% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 11
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
46% more capital invested
Capital invested by funds: $925M → $1.35B (+$426M)
29% more funds holding
Funds holding: 100 → 129 (+29)
21% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 42
70% less call options, than puts
Call options by funds: $2.56M | Put options by funds: $8.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.7M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$23.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$16M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$9.57M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TLP Group
Evanston,
Illinois
|
-$30.2M |
| 2 |
AC
Aisling Capital
New York
|
-$24.2M |
| 3 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$23.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.2M |
AIMT Hedge Fund Activity: Q4 2017 in Review
129 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2017, worth a combined $1.35B — up 46% from $925M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AIMT positions and 11 closed out — a net gain of 30 holders — while 33 added to existing stakes and 42 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $36.7M. The largest seller was TLP Group, cutting an estimated $30.2M.
- 129 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2017, up from 100 in Q3 2017.
- Funds reported $1.35B of Aimmune Therapeutics stock for Q4 2017, up 46% quarter-over-quarter.
- 41 funds opened new Aimmune Therapeutics positions in Q4 2017 and 11 closed out, a net change of +30 holders.
- The largest Aimmune Therapeutics buyer in Q4 2017 was T. Rowe Price Associates, an estimated $36.7M added.
- The largest Aimmune Therapeutics seller in Q4 2017 was TLP Group, an estimated $30.2M sold.
Based on aggregated 13F filings for Q4 2017.